Pharmacokinetic Study of Forodesine in Children With Relapsed or Refractory T-cell or B-cell Precursor Acute Lymphoblastic Leukaemia or T-cell Non- Hodgkin's Lymphoma. (BCX1777-108)
A Phase I/II Pharmacokinetic Study of Intravenous and Oral Forodesine in Children With Relapsed or Refractory T-cell or B-cell Precursor Acute Lymphoblastic Leukaemia or T-cell Non-Hodgkin's Lymphoma.
Sponsor: Innovative Therapies For Children with Cancer Consortium
Terminated
Slow Recruitment
Other terminated trials from Innovative Therapies For Children with Cancer Consortium
More terminations from Innovative Therapies For Children with Cancer Consortium
A PHASE1/PHASE2 clinical study on B-cell Precursor Acute Lymphoblastic Leukaemia and Relapsed or Refractory T-cell Acute Lymphoblastic Leukaemia, this trial is terminated or withdrawn. The trial is conducted by Innovative Therapies For Children with Cancer Consortium and has accumulated 6 data snapshots since 2009. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE1/PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE1_PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE1_PHASE2
First recorded
Mar 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Innovative Therapies For Children with Cancer Consortium
- Mundipharma Research Limited
For direct contact, visit the study record on ClinicalTrials.gov .